MSB Trading 2020 - a new dawn, page-9761

Time for a weekly reflection...

I'm glad the US election is over and we can get on with Mesoblast progress.

One week into October and our first catalyst didn't get announced and will be carried over in WK2.
Without this catalyst, we've basically range bounded and in line with the last 5 weeks now; since the 2nd of October the SP has gone from $3.19 to $3.20

However, next week is gonna be a busy week, potentially we can have up to 4 items in this coming week:

1. Results of 45% 2nd interim analysis - most likely a continuation of the trial. Whilst some SHs may think this will be negatively reflected by the market, I think the continuation announcement will be a neutral event, if not a slightly positive event - as nothing in the Covid-19 ARDS has not been priced into the current SP. A continuation is a vote of confidence that the trial is not futile and is therefore worthwhile to continue
2. CHF readout - This is huge news which has to come out some time. Why not aim for maximum exposure and get this out prior to the heart conference?
3. Heart conference - we should get presentation material for this event and maybe some noises from attendees
4. Notices of Type A meeting scheduled - On the 29th of October announcement we had "Mesoblast has formally requested a Type A meeting with the FDA to discuss a potential accelerated approval ofthe Biologics License Application (BLA) for remestemcel-L for the treatment of SR-aGVHD in children", so let's assume that this request was made on the day before this announcement, 28th of October - therefore, the FDA has up to the 10th/11th of November to respond. The only question is... will SHs be informed of the FDA decision on the Type A meeting request?

I've had enough of the range bound!
I'm looking forward to good news and the long anticipated re-rates

Hang in there MSB'ers - HODL
After several false starts, the fun part of the ride is just about to begin in earnest